I am a biomedical scientist with a Ph.D. in RNA Biology and more than 8 years of research experience exploring RNA-protein interactions, translational control, and RNA-based therapeutics. Currently, I am a Visiting Senior Research Specialist, the University of Illinois Chicago, investigating how translational GTPases such as LepA regulate ribosome function and fidelity. My research integrates RNA biology, molecular biochemistry, and small-molecule screening to uncover mechanisms driving cancer and neurological disorders. During my tenure at The Ohio State University, I identified novel RNA-protein interactions in DICER1 syndrome. I also identified that increased CAPN1 levels support RET and RAS-fueled growth by reducing NF1 levels. I discovered that combinatorial therapies combining CAPN1 inhibitors with Vandetinib or Selpercatinib achieve maximal efficacy in medullary thyroid cancer. In another project, I discovered that the RNA-binding protein Pumilio-3 modulates aberrant R-loops and R-loop-mediated DNA damage, which contribute to cancer and other neurological disorders. My Ph.D. work at the Indian Institute of Technology Indore led to the discovery of small molecules that target toxic CAG-repeat RNA in Huntington’s disease, paving the way for potential RNA-targeted therapies. With 20+ peer-reviewed publications in leading journals (Nucleic Acids Research, Chemical Reviews, Scientific Reports, Molecular Neurobiology), my interests lie at the intersection of RNA research.
I am a biomedical scientist with a Ph.D. in RNA Biology and more than 8 years of research experience exploring RNA-protein interactions, translational control, and RNA-based therapeutics. Currently, I am a Visiting Senior Research Specialist, the University of Illinois Chicago, investigating how translational GTPases such as LepA regulate ribosome function and fidelity. My research integrates RNA biology, molecular biochemistry, and small-molecule screening to uncover mechanisms driving cancer and neurological disorders. During my tenure at The Ohio State University, I identified novel RNA-protein interactions in DICER1 syndrome. I also identified that increased CAPN1 levels support RET and RAS-fueled growth by reducing NF1 levels. I discovered that combinatorial therapies combining CAPN1 inhibitors with Vandetinib or Selpercatinib achieve maximal efficacy in medullary thyroid cancer. In another project, I discovered that the RNA-binding protein Pumilio-3 modulates aberrant R-loops and R-loop-mediated DNA damage, which contribute to cancer and other neurological disorders. My Ph.D. work at the Indian Institute of Technology Indore led to the discovery of small molecules that target toxic CAG-repeat RNA in Huntington’s disease, paving the way for potential RNA-targeted therapies. With 20+ peer-reviewed publications in leading journals (Nucleic Acids Research, Chemical Reviews, Scientific Reports, Molecular Neurobiology), my interests lie at the intersection of RNA research.